Detalhe da pesquisa
1.
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.
Blood
; 143(7): 597-603, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048552
2.
Teclistamab in Relapsed or Refractory Multiple Myeloma.
N Engl J Med
; 387(6): 495-505, 2022 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35661166
3.
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study.
Haematologica
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38356463
4.
Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling.
Haematologica
; 109(3): 877-887, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646661
5.
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development.
Blood
; 138(17): 1583-1589, 2021 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34133718
6.
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.
Haematologica
; 108(10): 2753-2763, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37102598
7.
Teclistamab, a B-cell maturation antigenâ×âCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Lancet
; 398(10301): 665-674, 2021 08 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34388396
8.
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma.
Blood
; 136(2): 199-209, 2020 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32325491
9.
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma.
Blood
; 135(26): 2375-2387, 2020 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32299093
10.
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma.
Am J Hematol
; 97(6): 700-710, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35188691
11.
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.
Lancet Oncol
; 22(1): 142-154, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33301738
12.
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.
Br J Haematol
; 192(3): 522-530, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32501528
13.
Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease.
Blood
; 133(25): 2664-2668, 2019 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31010846
14.
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
Blood
; 134(16): 1337-1345, 2019 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31484647
15.
Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Biol Blood Marrow Transplant
; 25(9): 1703-1712, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31054983
16.
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
Eur J Haematol
; 102(6): 494-503, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30943323
17.
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
Br J Haematol
; 201(6): 1239-1244, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37057357
18.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
N Engl J Med
; 372(2): 142-52, 2015 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-25482145
19.
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.
Blood
; 127(6): 713-21, 2016 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26631116
20.
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.
Blood
; 127(9): 1151-62, 2016 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26668134